Acetylsalicylic acid mitigates erythropoietin-associated blood pressure increase in nonuremic rats

References

• Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. N Engl J Med 1987;316:73–8
   PubMed Web of Science ®Google Scholar
• Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemia patients with end-stage renal disease – results of a phase III multicenter clinical trial. Ann Int Med 1989;111:992–1000
   PubMed Web of Science ®Google Scholar
• Fischl CA, Galpin JE, Levine JD, et al. Recombinant human erythropoietin therapy for AIDS patients treated with AZT: a double-blind, placebo controlled clinical study. N Engl J Med 1990;322:1488–93
   PubMed Web of Science ®Google Scholar
• Raine AEG, Dphil FRCP, Roger SD. Effects of erythropoietin on blood pressure. Am J Kidney Dis 1991;18:76–83
   PubMed Web of Science ®Google Scholar
• Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008;74:791–8
   PubMed Web of Science ®Google Scholar
• Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071–84
   PubMed Web of Science ®Google Scholar
• Poux JM, Lartigue M, Chaisemartin RA, et al. Uraemia is necessary for erythropoietin-induced hypertension in rats. Clin Exp Pharm Physiol 1995;22:769–71
   PubMed Web of Science ®Google Scholar
• Bode-Boger SM, Boger RH, Kuhn M, et al. Endothelin release and shift in prostaglandin balance are involved in the modulation of vascular tone by recombinant erythropoietin. J Cardiovasc Pharmacol 1992;20:S25–8
   PubMed Web of Science ®Google Scholar
• Rodrigue ME, Lacasse S, Lariviere R, Lebel M. Cyclooxygenase inhibition with acetylsalicylic acid unmasks a role for prostacyclin in erythropoietin-induced hypertension in uremic rats. Can J Phys Pharmacol 2005;83:467–75
   PubMed Web of Science ®Google Scholar
• Briet M, Barhoumi T, Mian MOR, et al. Effects of recombinant human erythropoietin on resistance artery endothelial function in stage 4 chronic kidney disease role of oxidative stress and endothelin-1. J Am Heart Assoc 2013;2:e000128. doi: 10.1161/JAHA.113.000128
   PubMed Web of Science ®Google Scholar
• Valles J, Santos MT, Aznar J, et al. Erythrocytes metabolically enhance collagen-induced platelet responsiveness via increased thromboxane production, adenosine diphosphate release, and recruitment. Blood 1991;78:154–62
   PubMed Web of Science ®Google Scholar
• Caravaca F, Pizarro JL, Arrobas M, et al. Antiplatelet therapy and development of hypertension induced by recombinant human erythropoietin in uremic patients. Kidney Int 1994;45:845–55
   PubMed Web of Science ®Google Scholar
• Wu R, Lamontagne D, Champlain J. Antioxidative properties of acetylsalicylic acid on vascular tissues from normotensive and spontaneously hypertensive rats. Circulation 2002;105:387–92
   PubMed Web of Science ®Google Scholar
• El Midaoui A, Wu R, Champlain J. Prevention of hypertension, hyperglycemia and vascular oxidative stress by aspirin treatment in chronically glucose-fed rats. J Hypertens 2002;20:1407–12
   PubMed Web of Science ®Google Scholar
• Moncada S, Vane JR. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2 and prostacyclin. Pharmacol Rev 1979;30:293–331
   Web of Science ®Google Scholar
• Guyton AC, Coleman TG, Cowley AW, et al. A systems analysis approach to understanding long-range arterial blood pressure control and hypertension. Circ Res 1974;35:159–76
   Web of Science ®Google Scholar
• Rodrigue ME, Moreau C, Lariviere R, Lebel M. Relationship between eicosanoids and endothelin-1 in the pathogenesis of erythropoietin-induced hypertension in uremic rats. J Cardiovasc Pharmacol 2003;41:388–95
   PubMed Web of Science ®Google Scholar
• Muntzel M, Hannedouche T, Lacour B, Drueke T. Effect of erythropoietin on hematocrit and blood pressure in normotensive and hypertensive rats. J Am Soc Nephrol 1992;3:182–7
   PubMed Web of Science ®Google Scholar
• Muntzel M, Hannedouche T, Lacour B, Drüeke TB. Erythropoietin increases blood pressure in normotensive and hypertensive rats. Nephron 1993;65:601–4
   PubMed Web of Science ®Google Scholar
• Eggena P, Willsey P, Jamogotchain N, et al. Influence of recombinant human erythropoietin on blood pressure and tissue rennin–angiotensin systems. Am J Physiol 1991;261:E642–6
   PubMed Web of Science ®Google Scholar
• Jamogotchain N, Hu MS, Abdella P, et al. Recombinant human erythropoietin (rHuEPO)-induced hypertension (HPT): development of an experimental model [abstract]. Kidney Int 1989;35:313
   Web of Science ®Google Scholar
• Fishbane S, Nissenson AR. The new FDA label for erythropoietin treatment: how does it affect hemoglobin target? Kidney Int 2007;72:806–13
   PubMed Web of Science ®Google Scholar
• Heidenreich S, Rahn KH, Zidek W. Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int 1991;39:259–65
   PubMed Web of Science ®Google Scholar
• Vaziri ND, Zhou XJ, Naqvi F, et al. Role of nitric oxide resistance in erythropoietin-induced hypertension in rats with chronic renal failure. Am J Physiol 1996;271:113–22
   PubMed Web of Science ®Google Scholar
• Kaupke CJ, Kim S, Vaziri ND. Effect of erythrocyte mass on arterial blood pressure in dialysis patients receiving maintenance erythropoietin therapy. J Am Soc Nephrol 1994;4:1874–8
   PubMed Web of Science ®Google Scholar
• Rancourt ME, Rodrigue ME, Agharazii M, et al. Role of oxidative stress in erythropoietin-induced hypertension in rats. Am J Hypertens 2010;23:314–20
   PubMed Web of Science ®Google Scholar
• Liu Y, Xu Y, Thilo F, et al. Erythropoietin increases expression and function of transient receptor potential canonical 5 channels. Hypertension 2011;58:317–24
   PubMed Web of Science ®Google Scholar
• Taddei S, Vanhoutte PM. Role of endothelium in endothelin-evoked contractions in the rat aorta. Hypertension 1993;21:9–15
   PubMed Web of Science ®Google Scholar
• Takayasu-Okishio M, Terashita Z. Kondo K. Endothelin-1 and platelet activating factor stimulate thromboxane A2 biosynthesis in rat vascular smooth muscle cells. Biochem Pharmacol 1990;40:2713–17
   PubMed Web of Science ®Google Scholar
• de Nucci G, Thomas R, D’Orleans-Juste P, et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA 1988;85:9797–800
   PubMed Web of Science ®Google Scholar
• del Basso P, Argiolas L. Cardiopulmonary effects of endothelin-1 in the guinea pig: role of thromboxane A2. J Cardiovasc Pharmacol 1995;26:S120–2
   PubMed Web of Science ®Google Scholar
• D’Orleans-Juste P, Claing A, Telemaque S, et al. Block of endothelin-1-induced release of thromboxane A2 from the guinea pig lung and nitric oxide from the rabbit kidney by a selective ETB receptor antagonist, BQ-788. Br J Pharmacol 1994;113:1257–62
   PubMed Web of Science ®Google Scholar